Akari Therapeutics (AKTX) Projected to Post Earnings on Wednesday

Akari Therapeutics (NASDAQ:AKTX) will likely be issuing its Q1 2026 results after the market closes on Wednesday, May 20th. Analysts expect the company to announce earnings of ($1.33) per share for the quarter. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 19, 2026 at 7:00 AM ET.

Akari Therapeutics (NASDAQ:AKTX) last announced its quarterly earnings data on Monday, March 30th. The biopharmaceutical company reported ($2.68) EPS for the quarter, missing the consensus estimate of ($0.03) by ($2.65).

Akari Therapeutics Stock Performance

Shares of Akari Therapeutics stock traded up $0.11 during midday trading on Tuesday, hitting $3.61. The company had a trading volume of 26,300 shares, compared to its average volume of 25,173. The company has a fifty day simple moving average of $5.73 and a 200 day simple moving average of $11.07. Akari Therapeutics has a 12-month low of $3.02 and a 12-month high of $56.80.

Hedge Funds Weigh In On Akari Therapeutics

An institutional investor recently bought a new position in Akari Therapeutics stock. Armistice Capital LLC purchased a new stake in Akari Therapeutics PLC (NASDAQ:AKTX) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned 5.95% of Akari Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 5.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on AKTX shares. Maxim Group lowered shares of Akari Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, April 8th. HC Wainwright increased their price objective on shares of Akari Therapeutics to $27.00 and gave the company a “buy” rating in a research report on Wednesday, April 1st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Akari Therapeutics in a research report on Monday, April 20th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Akari Therapeutics presently has an average rating of “Hold” and an average target price of $89.00.

About Akari Therapeutics

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.